Literature DB >> 24107520

[Development of an anti-CCR4 antibody, mogamulizumab, the first approved antibody made by POTELLIGENT(®) technology].

Toshihiko Ishii.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24107520     DOI: 10.1254/fpj.142.167

Source DB:  PubMed          Journal:  Nihon Yakurigaku Zasshi        ISSN: 0015-5691


× No keyword cloud information.
  1 in total

1.  Depletion of regulatory T cells by targeting CC chemokine receptor type 4 with mogamulizumab.

Authors:  Xiao Ni; Timothy Langridge; Madeleine Duvic
Journal:  Oncoimmunology       Date:  2015-03-24       Impact factor: 8.110

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.